Top Markets
#1 Nesa Nesa +720.45%
#2 EXOD EXOD +22.78%
#3 MetaDAO MetaDAO +14.20%
#4 Venom Venom +10.59%
#5 Pons Pons +9.49%
#6 PondCoin PondCoin +8.69%
#7 Status Status +8.08%
#8 Wrapped NXM Wrapped NXM +8.03%
#9 Prom Prom +7.99%
#10 Ontology Gas Ontology Gas +7.17%
Coin of the day
Nesa Nesa
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Connect Biopharma Holdings Limited Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited

CNTB
Rang in aandelen #19727
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical... Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
Aandeelprijs
$2.42
Laatst gesynchroniseerd: 2026-08-25
Marktkapitalisatie
$152.37M
Verandering (1 dag)
5.22%
Verandering (1 jaar)
39.88%
Land
US
Handel Connect Biopharma Holdings Limited (CNTB)

Categorie

Healthcare
Winst voor Connect Biopharma Holdings Limited (CNTB)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Connect Biopharma Holdings Limited bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Connect Biopharma Holdings Limited van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH